Jan 07, 2020
Ipsen Announces the Availability of the Newly Designed Delivery System for Somatuline® Autogel® (lanreotide injection)
Dec 12, 2018
Entrinsic Health Solutions and Markey Cancer Center Launch Phase II Study for Neuroendocrine Tumor Patients with Quality of Life-Limiting Diarrhea
Oct 16, 2018
Health Canada approves XERMELO(TM) (telotristat ethyl) for the treatment of adult patients suffering from refractory carcinoid syndrome diarrhea(1)
Oct 09, 2018
Navigating Neuroendocrine Tumors
Feb 13, 2018
Health Canada approves Ipsen's Somatuline® Autogel® for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)
Jan 26, 2018
FDA approves new treatment for certain digestive tract cancers
Nov 08, 2017
Lexicon Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides A Business Update
Oct 19, 2017
Clinical Data from Phase 1 PK/PD Study of Octreotide for Intranasal Delivery to be Presented at North American Neuroendocrine Tumor Society Symposium
Sep 19, 2017
European Commission Approves XERMELO® (Telotristat Ethyl) For The Treatment Of Carcinoid Syndrome Diarrhea In Combination With Somatostatin Analog Therapy
Sep 07, 2017
Lexicon Pharmaceuticals Announces Four Data Presentations At The European Society Of Medical Oncology 2017 Congress
Aug 01, 2017
Lexicon Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides A Business Update
Jul 21, 2017
Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo® (Telotristat Ethyl)
Jun 19, 2017
NCCN Guidelines For Neuroendocrine Tumors Include XERMELO In Combination With Somatostatin Analog Therapy As A Recommended Treatment Option For Patients With Carcinoid Syndrome Diarrhea
Jun 08, 2017
New Data From Biotheranostics, Inc. Further Demonstrate the Value of CancerTYPE ID to Help Identify Metastatic Cancers with an Unknown or Unclear Tumor Type Diagnosis